Anzeige
Mehr »
Lynx Broker
Login
Sonntag, 17.11.2019 Börsentäglich über 12.000 News von 617 internationalen Medien
Millionenauftrag für Microcap! Entsprechende Reaktion am Montag erwartet…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2ARHW ISIN: US8673287004 Ticker-Symbol: RYIP 
Frankfurt
15.11.19
08:20 Uhr
0,346 Euro
-0,018
-4,95 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
SUNESIS PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
SUNESIS PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,348
0,350
18:35
0,330
0,352
15.11.

Aktuelle News zur SUNESIS PHARMACEUTICALS Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
SUNESIS PHARMACEUTICALS Aktien jetzt im kostenlosen Demokonto handeln!
DoSunesis Pharmaceuticals - Insight into the future of SNS-510731Sunesis recently presented a poster on the preclinical findings of its PDK1 inhibitor SNS-510. Surprisingly, researchers found that the drug was most active in cancer cell lines with mutations in the...
► Artikel lesen
DiSUNESIS PHARMACEUTICALS INC - 10-Q, Quaterly Report-
DiSUNESIS PHARMACEUTICALS INC - 8-K, Current Report-
08.11.Sunesis Pharmaceuticals, Inc.: Sunesis Pharmaceuticals to Present at 28th Annual Credit Suisse Healthcare Conference-
06.11.Sunesis Pharmaceuticals, Inc.: Sunesis Pharmaceuticals Announces Presentation at 61st American Society of Hematology ...-
16.10.Sunesis Pharmaceuticals, Inc.: Sunesis Pharmaceuticals Announces Presentation of SNS-510 Preclinical Data at the ...1
19.09.SUNESIS PHARMACEUTICALS INC - 8-K, Current Report-
19.09.Sunesis Pharmaceuticals, Inc.: Sunesis Pharmaceuticals Appoints Dr. Nicole Onetto to the Board of Directors-
08.08.Sunesis Pharmaceuticals, Inc. (SNSS) Interim CEO Dayton Misfeldt on Q2 2019 Results - Earnings Call Transcript4
07.08.SUNESIS PHARMACEUTICALS INC - 10-Q, Quaterly Report-
07.08.Sunesis Pharmaceuticals EPS beats by $0.011
11.07.Sunesis prices stock offering; shares down 27% premarket4
11.07.The Daily Biotech Pulse: Neurocrine's Parkinson's Drug Accepted For Review, Sunesis Offering, No Headaches For Biohaven's Migraine Drug16
11.07.Sunesis Pharmaceuticals, Inc.: Sunesis Announces Pricing of $25 Million Offering of Securities5
10.07.Sunesis Pharmaceuticals, Inc.: Sunesis Announces Proposed Public Offering of Common Stock and Preferred Stock-
09.07.SUNESIS PHARMACEUTICALS INC - 8-K, Current Report1
08.07.Sunesis Pharmaceuticals, Inc.: Sunesis Pharmaceuticals Announces Executive Promotions and Provides Clinical Update1
24.06.Sunesis Pharmaceuticals - EHA data released52Sunesis provided an update at the European Hematology Association (EHA) meeting on its ongoing Phase Ib/II study of vecabrutinib in patients with B-cell malignancies, providing detailed data on the...
► Artikel lesen
06.06.SUNESIS PHARMACEUTICALS INC - 8-K, Current Report2
22.03.Edison Investment Research Limited: Edison Issues Outlook on Sunesis Pharmaceuticals (SNSS)57LONDON, UK / ACCESSWIRE / March 22, 2019 / Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) is currently in the dose-escalation portion of the Phase Ib/II study of its BTK inhibitor vecabrutinib, and the...
► Artikel lesen
Seite:  Weiter >>
22 Nachrichten in den letzten 12 Monaten

Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1